UAB High Throughput DNA AutoGenPrep 965

描述（由申请人提供）：转基因小鼠设施（转基因小鼠实验室）成立于1991年，是为UAB研究者有效生产转基因动物模型的集中核心。该共享设施主要由大学中心（综合癌症中心（CCC），综合关节炎，肌肉骨骼和自身免疫中心（CAMAC），隐性多囊肾病核心中心和代谢性骨病中心（CMBD））维持的P30赠款以及所提供服务的用户费用提供支持。自成立以来，该中心已为UAB研究人员完成了1000多个DNA或ES细胞显微注射项目，仅去年一年就有30多名UAB研究人员使用该设施。本提案要求提供资金，用于购买一台最先进的AutoGenPrep 965（AGP965）全自动高通量机器人仪器，用于核酸提取和纯化，并将其安置在转基因小鼠设施内。虽然AGP 965的设计目的是在几个小时内从多达四个96深孔板中纯化DNA，以用于各种下游应用，但其与该应用一起使用的主要目的是从小鼠组织中纯化高质量的基因组DNA样本，以促进对与多个NIH赠款相关的大量小鼠进行基因分型。该应用程序代表了该机构内广泛的NIH资助的用户群，其中介绍了18个主要用户的研究工作。AGP965技术的重要性见附件A，其中列出了共同研究者关于该提案的出版物，这些出版物来自使用转基因小鼠模型的项目。表3和表4提供了联邦对主要用户和次要用户的支持，主要用户群的使用率估计超过80%。AGP965仪器是一个重要的资源，它将通过多个NIH同行评审的研究赠款显着增强研究项目。

DESCRIPTION (provided by applicant): The Transgenic Mouse Facility (TMF) was established in 1991 as a centralized core for the efficient production of transgenic animal models for UAB investigators. The shared facility is supported primarily by P30 Grants maintained by University Centers (Comprehensive Cancer Center (CCC), Comprehensive Arthritis, Musculoskeletal and Autoimmunity Center (CAMAC), Recessive Polycystic Kidney Disease Core Center, and Center for Metabolic Bone Disease (CMBD)), and by user fees for services provided. Since inception, the TMF has completed more than 1000 DNA or ES cell microinjection projects for UAB investigators with more than 30 UAB investigators using the facility within the last year alone. In this proposal, funds are requested to purchase a state-of- the-art AutoGenPrep 965 (AGP965) fully automated high throughput robotic instrument for nucleic extraction and purification to be housed in the Transgenic Mouse Facility. While the AGP965 is designed to purify DNA from up to four 96 deep well plates in a matter of a few hours for a wide variety of downstream applications, the main intent of its use with this application is the purification of high quality genomic DNA from mouse tissue samples to facilitate genotyping of a large number of mice associated with multiple NIH grants. This application represents a broad, NIH-funded user base within the institution, of which the research endeavors of 18 major users are presented. The importance of the AGP965 technology is illustrated in Exhibit A, which lists the publications from the co-investigators on this proposal that resulted from projects using transgenic mouse models. Federal support of the major and minor users is provided in Tables 3 and 4, with an estimated usage of greater than 80% by the major user base. The AGP965 instrument is an essential resource that will significantly enhance research projects by multiple NIH peer reviewed research grants.